On Sunday, July 13, Biocentury TV This Week held a debate on drug pricing and its impact on healthcare costs.
From Biocentury TV:
The $84,000 annual price tag attached to Sovaldi, Gilead's curative drug for Hepatitis C, has sparked a firestorm. Key stakeholders are accusing the biotech of price gouging and some insurers are even curtailing access to the life-saving drug. Conversely, industry maintains the focus needs to be on value, not just price.
To discuss this contentious issue, BioCentury This Week is joined by four individuals who represent key spheres of influence:
• John Rother, President and CEO of the National Coalition on Health Care
• Lori Reilly, Executive Vice President for Policy and Research at PhRMA
• Dr. Russell Medford, Managing Partner at the Salutramed Group and former CEO and founder of several biotech companies
• Brendan Buck, Vice President of Communications at America's Health Insurance Plans and former Press Secretary for House Speaker John Boehner